Pilot study of erlotinib in patients with acute myeloid leukemia

Hamid Sayar, Magdalena Czader, Chirag Amin, Mary Cangany, Heiko Konig, Larry Cripe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We conducted a pilot study to investigate clinical efficacy of tyrosine kinase inhibitor erlotinib in the treatment of acute myeloid leukemia (AML). A total of 11 patients with de novo AML were treated, including 2 with relapsed and/or refractory disease and 9 older patients with previously untreated AML. Patients with high baseline leukocyte count were excluded. Erlotinib was given orally at 150. mg per day continuously in 28-day cycles. The treatment was tolerated well, and no toxicities were observed. An initial reduction in circulating blasts, followed by disease progression, was observed in 2 patients. Nine other patients did not demonstrate any response in blood or bone marrow. Baseline and post-cycle 1 flow-cytometry were performed on bone marrow blasts to investigate signs of differentiation. No immunophenotypic changes suggestive of differentiation were observed. This pilot study did not demonstrate response to standard doses of erlotinib in patients with AML.

Original languageEnglish
Pages (from-to)170-172
Number of pages3
JournalLeukemia Research
Volume39
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Acute Myeloid Leukemia
Bone Marrow
Leukocyte Count
Protein-Tyrosine Kinases
Disease Progression
Erlotinib Hydrochloride
Flow Cytometry
Therapeutics

Keywords

  • Acute myeloid leukemia
  • AML
  • EGFR
  • Erlotinib
  • Pilot study

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology
  • Medicine(all)

Cite this

Pilot study of erlotinib in patients with acute myeloid leukemia. / Sayar, Hamid; Czader, Magdalena; Amin, Chirag; Cangany, Mary; Konig, Heiko; Cripe, Larry.

In: Leukemia Research, Vol. 39, No. 2, 01.02.2015, p. 170-172.

Research output: Contribution to journalArticle

Sayar, Hamid ; Czader, Magdalena ; Amin, Chirag ; Cangany, Mary ; Konig, Heiko ; Cripe, Larry. / Pilot study of erlotinib in patients with acute myeloid leukemia. In: Leukemia Research. 2015 ; Vol. 39, No. 2. pp. 170-172.
@article{2512c2d8954a4ac49d1ee3b5c9060d02,
title = "Pilot study of erlotinib in patients with acute myeloid leukemia",
abstract = "We conducted a pilot study to investigate clinical efficacy of tyrosine kinase inhibitor erlotinib in the treatment of acute myeloid leukemia (AML). A total of 11 patients with de novo AML were treated, including 2 with relapsed and/or refractory disease and 9 older patients with previously untreated AML. Patients with high baseline leukocyte count were excluded. Erlotinib was given orally at 150. mg per day continuously in 28-day cycles. The treatment was tolerated well, and no toxicities were observed. An initial reduction in circulating blasts, followed by disease progression, was observed in 2 patients. Nine other patients did not demonstrate any response in blood or bone marrow. Baseline and post-cycle 1 flow-cytometry were performed on bone marrow blasts to investigate signs of differentiation. No immunophenotypic changes suggestive of differentiation were observed. This pilot study did not demonstrate response to standard doses of erlotinib in patients with AML.",
keywords = "Acute myeloid leukemia, AML, EGFR, Erlotinib, Pilot study",
author = "Hamid Sayar and Magdalena Czader and Chirag Amin and Mary Cangany and Heiko Konig and Larry Cripe",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2014.11.022",
language = "English",
volume = "39",
pages = "170--172",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Pilot study of erlotinib in patients with acute myeloid leukemia

AU - Sayar, Hamid

AU - Czader, Magdalena

AU - Amin, Chirag

AU - Cangany, Mary

AU - Konig, Heiko

AU - Cripe, Larry

PY - 2015/2/1

Y1 - 2015/2/1

N2 - We conducted a pilot study to investigate clinical efficacy of tyrosine kinase inhibitor erlotinib in the treatment of acute myeloid leukemia (AML). A total of 11 patients with de novo AML were treated, including 2 with relapsed and/or refractory disease and 9 older patients with previously untreated AML. Patients with high baseline leukocyte count were excluded. Erlotinib was given orally at 150. mg per day continuously in 28-day cycles. The treatment was tolerated well, and no toxicities were observed. An initial reduction in circulating blasts, followed by disease progression, was observed in 2 patients. Nine other patients did not demonstrate any response in blood or bone marrow. Baseline and post-cycle 1 flow-cytometry were performed on bone marrow blasts to investigate signs of differentiation. No immunophenotypic changes suggestive of differentiation were observed. This pilot study did not demonstrate response to standard doses of erlotinib in patients with AML.

AB - We conducted a pilot study to investigate clinical efficacy of tyrosine kinase inhibitor erlotinib in the treatment of acute myeloid leukemia (AML). A total of 11 patients with de novo AML were treated, including 2 with relapsed and/or refractory disease and 9 older patients with previously untreated AML. Patients with high baseline leukocyte count were excluded. Erlotinib was given orally at 150. mg per day continuously in 28-day cycles. The treatment was tolerated well, and no toxicities were observed. An initial reduction in circulating blasts, followed by disease progression, was observed in 2 patients. Nine other patients did not demonstrate any response in blood or bone marrow. Baseline and post-cycle 1 flow-cytometry were performed on bone marrow blasts to investigate signs of differentiation. No immunophenotypic changes suggestive of differentiation were observed. This pilot study did not demonstrate response to standard doses of erlotinib in patients with AML.

KW - Acute myeloid leukemia

KW - AML

KW - EGFR

KW - Erlotinib

KW - Pilot study

UR - http://www.scopus.com/inward/record.url?scp=84921439569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921439569&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.11.022

DO - 10.1016/j.leukres.2014.11.022

M3 - Article

C2 - 25498508

AN - SCOPUS:84921439569

VL - 39

SP - 170

EP - 172

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -